What is claimed:
1. A composition for reducing caloric intake comprising glycomacropeptide that stimulates the release of cholecystokinin following ingestion and suitable excipients for ingestion in the substantial absence of other agents known to stimulate the release of cholecystokinin following ingestion.
2. A composition in accordance with claim 1, wherein said composition is in powder form and further comprises excipients suitable for the ingestion of said powder.
3. A composition in accordance with claim 1, wherein said composition is in powder form and further comprises excipients suitable for the addition of said powder to food.
4. A composition in accordance with claim 1, wherein said composition is in powder form and further comprises excipients suitable for the addition of said powder to a liquid to form a drink.
5. A composition in accordance with claim 1, wherein said composition is in the form of a tablet that may be chewed or swallowed, and said excipients are suitable for the formulation of such tablets.
6. A composition in accordance with claim 1, wherein said composition comprises from about 30% to about 90% by weight of pure glycomacropeptide.
7. A composition in accordance with claim 1, wherein said glycomacropeptide is present as a purified whey preparation containing at least thirty percent by weight of pure glycomacropeptide.
8. A composition in accordance with claim 7, wherein said whey preparation contains at least about sixty percent by weight of pure glycomacropeptide.
9. A composition in accordance with claim 1 additionally containing an agent that achieves caloric reduction by a mode of action other than the stimulation of the release of cholecystokinin following ingestion.
10. A composition in accordance with claim 9, wherein said agent is a stimulant.
11. A composition in accordance with claim 10, wherein said stimulant is caffeine or ephedrine.
12. A composition in accordance with claim 9, wherein said agent is a sympathomimetic agent.
13. A composition in accordance with claim 9, wherein said agent is a lipase inhibitor.
14. A method of reducing the caloric intake in an individual in need thereof comprising causing said individual to ingest with a meal or up to about ten minutes prior thereto an effective amount of a composition that stimulates the release of cholecystokinin following ingestion comprising glycomacropeptide and suitable excipients for ingestion in the substantial absence of other agents known to stimulate the release of cholecystokinin following ingestion.
15. A method in accordance with claim 14, wherein a sufficient amount of said composition is ingested to provide from about 0.2 to about 3 grams of pure glycomacropeptide.
16. A method in accordance with claim 15, wherein a sufficient amount of said composition is ingested to provide from about 1 to about 2 grams of pure glycomacropeptide.
17. A method in accordance with claim 14, wherein said composition is in powder form that is added to a food prior to ingestion.
18. A method in accordance with claim 14, wherein said composition is in powder form that is added to a liquid to form a drink prior to ingestion.
19. A method in accordance with claim 18, wherein said liquid is selected from the group consisting of water, apple juice, orange juice, grape juice, grapefruit juice, cranberry juice, coffee, tea, milk, milkshakes, broth, and soup consomm.
20. A method in accordance with claim 14, wherein said composition additionally contains an agent that achieves caloric reduction by a mode of action other than the stimulation of the release of cholecystokinin following ingestion.
21. A method in accordance with claim 20, wherein said agent is a stimulant.
22. A method in accordance with claim 21, wherein said stimulant is caffeine or ephedrine.
23. A method in accordance with claim 20, wherein said agent is a sympathomimetic agent.
24. A method in accordance with claim 20, wherein said agent is a lipase inhibitor.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. Aerosol administration device comprising a generator of particles of size between 10 nm and 200 \u03bcm for forming an aerosol, a mouthpiece or oral mask for oral administration of the aerosol to a patient during a nasal expiration phase or during a respiratory pause phase preceding nasal expiration, and a source of gas or pressure for conveying the particles, wherein the particle generator is operated manually or automatically, the mouthpiece and particle generator constituting an airtight assembly during aerosol administration phases connected to the patient’s mouth, the mouthpiece penetrates beyond teeth of a patient by a maximum length of 4 cm and administers aerosol for the nasal cavities, rhinopharynx or paranasal sinuses during the aerosol administration phases, such that the aerosol is successively conveyed through an internal circuit to the mouth, then the rhinopharynx, then the nasal fossae and sinuses, and then said aerosol escapes through one or both of the patient’s nostrils, and the device does not allow oral expiration during the aerosol administration phases, the aerosol particles not being directed to the lungs.
2. Device according to claim 1, wherein the mouthpiece is airtight and penetrates beyond the teeth by a minimum length of 1 cm.
3. Device according to claim 1, wherein triggering of the generation of the aerosol is achieved automatically with the aid of an electric, pneumatic or mechanical means.
4. Device according to claim 3, wherein the means is connected to the patient’s mouth and comprises a nosepiece connected to the patient’s nostrils, and in that said nosepiece is connected to a mechanical means allowing triggering of a piston during the patient’s nasal expiration phase.
5. Device according to claim 3, wherein the generator comprises a pneumatic nebulizer connected to the patient’s mouth supplied by an air compressor via a tube, said nebulizer being connected to the mouthpiece and to a tube connected to a pressure sensor contained in the compressor, and in that the nebuliser is triggered during the patient’s nasal expiration phase, detected by the pressure sensor connected in a sealed manner to the patient’s oral cavity.
6. Device according to claim 3, wherein the generator includes a nebulizer and a storage chamber connected to the mouth and to a source of gas, said nebulizer being connected to the mouthpiece and to a tube connected to a pressure sensor contained in the gas source, and the nebulizer is triggered during the patient’s nasal expiration phase, detected by the pressure sensor connected in a sealed manner to the patient’s oral cavity.
7. Device according to claim 1, wherein the generator comprises a pneumatic nebulizer associated with an acoustic wave and particle-administration means, and said nebulizer is connected to the mouth and supplied by an air compressor via a tube, said nebulizer having a connection near the mouthpiece to receive a tube connected to a pressure sensor contained in said compressor, the assembly being sealed at the patient’s mouth, and further comprising a nosepiece connected to one of the patient’s two nostrils, and a tube conveying acoustic waves connecting an acoustic-wave source and the nosepiece.
8. Device according to claim 1, wherein the mouthpiece is connected to a generator of particles of powder operating with the aid of an external gas reservoir.
9. Device according to claim 1, wherein the generator of particles comprises a pneumatic nebuliser connected to the patient’s mouth and supplied by an air compressor via a tube, said nebulizer having a connection near the mouthpiece to receive a tube connected to a pressure sensor contained in said compressor, and the assembly is sealed at the patient’s mouth.
10. Device according to claim 1, wherein the generator of particles comprises a nebulizer associated with a storage chamber connected at one end to the mouth and at an other end to an air source, and said nebulizer has a connection near the mouthpiece designed to receive a tube connected to a pressure sensor contained in the air source, the assembly being sealed at the patient’s mouth.
11. Device according to claim 1, wherein the generator of particles and the source of gas or pressure comprises an aerosol generator including particles and pressurized gas, an inspiratory valve and a pressure sensor allowing triggering of the aerosol during the expiratory phase, and further comprising a nosepiece having a narrow section and connected to both nostrils.
12. Device according to claim 1, wherein the assembly defines a sealed circuit connected to the patient’s mouth comprising the mouthpiece connected to a generator of particles of powder operating with the aid of an external gas reservoir administering particles of powder only during a first period of generation of gas by deformation of said reservoir.